CCAPS Annual Meeting
Meeting Co-Sponsor: Colorado Chapter of the American Academy of Pediatrics
Saturday, April 13th, 2013
Update on the Assessment and Treatment of Autism Spectrum Disorders
Presenter: Robert L Hendren, D.O.
Registration Form
Robert L. Hendren, D.O., is Professor of Psychiatry and Behavioral Science; Director of Child and Adolescent Psychiatry and Vice Chair of the Department of Psychiatry at the University of California, San Francisco. From 2001-2009, he was Professor of Psychiatry and Executive Director and Tsakopoulos-Vismara Chair at the University of California, Davis M.I.N.D. Institute (Medical Investigation of Neurodevelopmental Disorders). Dr. Hendren is Past President (2007-2009) of the American Academy of Child and Adolescent Psychiatry.
Panelists: Dr. Edward Goldson is a pediatrician in Denver; Diane Osaki, OTR, is the Early Start Denver Model Director of Firefly Autism; and Audrey Blakeley-Smith, Ph.D., is at the School of Medicine JFK Partners.
Schedule:
7:00 a.m. - 8:00 a.m.
Registration & Continental Breakfast
8:00 a.m. - 9:00 a.m.
Session I: Is there an increase in autism? Why and why not? What causes it? What should be considered in the differential diagnosis?
9:00 a.m. - 9:15 a.m. Break
9:15 a.m. - 10:15 a.m.
Session II: When to do a comprehensive biomedical autism assessment?
Treatment Part I - Behavioral, Speech, OT
10:15 a.m. - 10:30 a.m. Break
10:30 a.m. - 11:30 p.m.
Session III: When to consider psychopharmacologic and biomedical treatments and what are the pros and cons of each choice?
11:30 a.m.-11:45 a.m. Break
11:45 a.m. - 12:45 p.m.
Session IV: Panel Q & A
Robert L. Hendren, D.O., Edward Goldson, M.D., Diane Osaki, OTR, and Audrey Blakeley-Smith, Ph.D.
Objectives of the Meeting:
1) Review new research suggesting novel models for understanding the etiology of ASD and the implications of this for assessing and treating patients with autism.
2) Consider current pharmacologic and emerging "biomedical" treatments and their evidence for treating ASD.
3) Discuss the implications of this "paradigm shift" for translational research, clinical assessment and integrated treatments.
